Artiva Biotherapeutics, Inc. (ARTV) Stock Statistics & Valuation Metrics

Artiva Biotherapeutics, Inc. has a market cap or net worth of $49.21M. The enterprise value is ―.

Artiva Biotherapeutics, Inc. has 24,363,120 shares outstanding. The number of shares has decreased by -2.65% in one year.

Artiva Biotherapeutics, Inc.’s return on equity (ROE) is -0.31 and return on invested capital (ROIC) is -33.46%.

The current PE Ratio of Artiva Biotherapeutics, Inc. is -1.94. Artiva Biotherapeutics, Inc.’s PEG ratio is ―.

In the last 12 months, Artiva Biotherapeutics, Inc. had revenue of 251.00K and earned -58.49M in profits. Earnings per share was -5.20.

In the last 12 months, operating cash flow was -55.03M and capital expenditures -642.00K, giving a free cash flow of -55.67M billion.

Artiva Biotherapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Artiva Biotherapeutics, Inc. upcoming earnings date is Aug 28, 2025, TBA Not Confirmed.

Artiva Biotherapeutics, Inc. as a current ratio of 15.39, with Debt / Equity ratio of 7.69%

In the past 12 months, Artiva Biotherapeutics, Inc. has paid 0.00 in taxes.

Artiva Biotherapeutics, Inc. EV to EBITDA ratio is -1.35, with an EV/FCF ratio of -1.57.

Artiva Biotherapeutics, Inc. has $185.43M in cash and marketable securities with $14.35M in debt, giving a net cash position of -$171.07M billion.

Gross margin is 100.00%, with operating margin of -26805.58%, and net profit margin of -23303.98%.

The average price target for Artiva Biotherapeutics, Inc. is $19.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy